Breaking News Instant updates and real-time market news.

SFIX

Stitch Fix

$34.32

3.21 (10.32%)

, UA

Under Armour

$20.96

0.15 (0.72%)

10:49
07/10/18
07/10
10:49
07/10/18
10:49

Stitch Fix rises after launching Stitch Fix Kids, KeyBanc Overweight initiation

Shares of Stitch Fix (SFIX) are rising after the online personal styling service launched an offering for kids and an analyst started coverage of the stock with an Overweight rating. STITCH FIX KIDS: On Monday, Stitch Fix announced the launch of its kids offering and allowed parents to sign up to request a Fix for their child. Stitch Fix Kids, which does not require a subscription or membership, offers clothing and accessories available in sizes 2T-14 with average prices ranging from $10 to $35 per item. Kids Fixes include eight to 12 items and at launch, more than 50 brands are offered, including Under Armour (UA, UAA), Nike (NKE), TOMS, DL1961, Hanna Andersson, Threads 4 Thought, Joules, Sovereign Code, Tailor Vintage and more. Stitch Fix also introduced its own exclusive brand, Rumi + Ryder, a collection of everyday playwear and essentials for boys and girls. Parents can manage their kid's profile directly from their own, the company said. New and existing clients can fill out a Style Profile with their child, and pick the date to receive their first Kids Fix. Clients pay a $20 styling fee, which is applied towards any item purchased in their child's Fix. Clients buy what they like and return the rest, with free shipping both ways. If all items are kept, the client receives a 25% discount, it added. EXECUTIVE COMMENTARY: "At Stitch Fix, our goal has always been to help our clients discover products and styles they love," CEO Katrina Lake said. "Now, we want to inspire the same confidence in our littlest clients. Stitch Fix Kids is a fun and engaging way for kids to find clothes they love and feel their best in, while saving parents time." ANALYST VIEW: On Monday, KeyBanc Capital Markets analyst Edward Yruma initiated Stitch Fix with an Overweight rating and a $38 price target. The analyst said in a research note that he believes the company's unique combination of data-driven human curation will enable it to gain share in the $340B softlines market. The use of data is a significant advantage to the traditional retail competitive set and allows Stitch Fix to develop a scalable, yet highly human, recommendation model, Yruma said. He sees share gains continuing in the core women's market and expects men's, plus and kids to assist in further accelerating growth. Yruma separately downgraded Nordstrom (JWN) and Urban Outfitters (URBN) to Sector Weight. PRICE ACTION: Stitch Fix rose 10.3% to $34.31 in morning trading.

SFIX

Stitch Fix

$34.32

3.21 (10.32%)

UA

Under Armour

$20.96

0.15 (0.72%)

UAA

Under Armour

$22.37

0.1 (0.45%)

NKE

Nike

$77.65

0.35 (0.45%)

JWN

Nordstrom

$51.11

-2.43 (-4.54%)

URBN

Urban Outfitters

$45.60

-0.2 (-0.44%)

  • 10

    Jul

  • 16

    Jul

  • 17

    Jul

  • 18

    Jul

  • 19

    Jul

SFIX Stitch Fix
$34.32

3.21 (10.32%)

03/13/18
JPMS
03/13/18
NO CHANGE
JPMS
Stitch Fix lock-up tomorrow could bring near-term weakness, says JPMorgan
JPMorgan analyst Doug Anmuth says active client growth modestly accelerated to 31% year-over-year, leading to Stitch Fix's fourth straight quarter of 25% year-over-year revenue growth. The analyst, however, keeps a Neutral rating on the shares with a $26 price target following last night's Q4 results. He expects advertising spend and headcount growth will continue to weigh on margins. Further, Anmuth estimates 31M shares will be released from lock-up tomorrow, March 14, before the market open, versus the current 9M share float. This could create near-term weakness in the shares, Anmuth tells investors in a research note.
03/19/18
BUCK
03/19/18
INITIATION
BUCK
Neutral
Stitch Fix initiated with a Neutral at Buckingham
07/09/18
KEYB
07/09/18
INITIATION
Target $38
KEYB
Overweight
Stitch Fix initiated with an Overweight at KeyBanc
KeyBanc started Stitch Fix with an Overweight rating and $38 price target.
06/22/18
WBLR
06/22/18
NO CHANGE
WBLR
William Blair does not see tax ruling impacting e-commerce companies
William Blair analyst Ryan Domyancic does not believe yesterday's Supreme Court ruling on state sales tax will have an adverse impact on the e-commerce companies he covers: Amazon.com (AMZN), Wayfair (W), and Stitch Fix (SFIX). He notes that his findings indicate that Amazon's price discount is not driven by a lack of sales tax. Further, Stitch Fix's primary value proposition is customized style rather than deep discounts, Domyancic tells investors in a research note. On Wayfair, the analyst thinks the collection of sales tax in incremental states has not affected its growth over the past several years.
UA Under Armour
$20.96

0.15 (0.72%)

07/10/18
LEHM
07/10/18
NO CHANGE
Target $20
LEHM
Overweight
Under Armour well positioned to meet or beat Q2 guidance, says Barclays
In a research note titled "We Can Smell What Plank Is Cooking," Barclays analyst Matthew McClintock says Under Armour (UAA) appears well positioned to meet or exceed guidance for Q2. The analyst, however, questions if that is enough to make the stock work with the shares up 54% year-to-date. Even if Under Armour beats, the recent stock price appreciation likely limits upside in the stock from here, McClintock tells investors. He believes the company is more than halfway through its turnaround plan "with an inflection on the horizon." The analyst also believes that its guidance sets up for easy compares in the back-half of the year. McClintock has an Overweight rating on Under Armour with a $20 price target, below the stock's current levels.
07/02/18
JPMS
07/02/18
NO CHANGE
Target $16
JPMS
Underweight
Under Armour price target raised to $16 from $13 at JPMorgan
JPMorgan analyst Matthew Boss raised his price target for Under Armour (UAA) to $16 after adjusting his model to reflect recent earnings reports and company news. The analyst, however, keeps an Underweight rating on the shares. Under Armour faces a worsening North America athletic retail environment, driven by bankruptcies and store closures, as well as increased competition from adidas and Puma, Boss tells investors in a research note.
06/29/18
JEFF
06/29/18
NO CHANGE
Target $75
JEFF
Buy
Nike shares remain expensive despite strong Q4, says Jefferies
Jefferies analyst Randal Konik says that while Nike last night reported strong Q4 results, the shares remain expensive. The analyst raised his price target for the stock to $75 from $68 and reiterates a Hold rating on the name. Konik continues to like Foot Locker (FL) as a less expensive way to play Nike, and Under Armour (UAA) as a better way to play a strengthening athletic space.
06/21/18
UBSW
06/21/18
INITIATION
Target $24
UBSW
Neutral
Under Armour initiated with a Neutral at UBS
UBS analyst Jay Sole started Under Armour with a Neutral rating and $24 price target.
UAA Under Armour
$22.37

0.1 (0.45%)

NKE Nike
$77.65

0.35 (0.45%)

06/29/18
BERN
06/29/18
NO CHANGE
Target $84
BERN
Outperform
Nike price target raised to $84 from $76 at Bernstein
Bernstein analyst Jamie Merriman reiterated an Outperform rating on Nike and raised her price target to $84 from $76 following the company's Q4 results based on her belief that product innovation will continue to drive long-term revenue growth and the mix shift under way to Direct-to-Consumer will lead to margin upside, forecasting a 17% EPS CAGR over the next five years. In a research note to investors, Merriman contends that over the last few months, optimism that Nike has "righted the ship" has emerged, and that momentum is expected to continue into 2019 with the ramp of products like Vapormax and Epic React, the rollout of Nike's digital initiatives internationally and events like the World Cup.
06/29/18
FBCO
06/29/18
NO CHANGE
Target $90
FBCO
Outperform
Nike price target raised to $90 from $78 at Credit Suisse
Credit Suisse analyst Michael Binetti reiterated an Outperform rating on Nike and raised his price target to $90 from $78 following the company's Q4 results, telling investors in a research note that the results signal that several years of bloated inventories, lackluster innovation and market share losses are now clearly inflecting. Binetti thinks Nike is well positioned to monetize reversing multi-year share losses to drive upside to guidance, but notes that Nike's transformation acceleration to more of a direct/digital retailer will put significant upward pressure on the economics of the business vs. historical levels.
06/29/18
STFL
06/29/18
NO CHANGE
Target $90
STFL
Buy
Nike business model shift showing early benefits, says Stifel
Stifel analyst Jim Duffy noted that Nike's Q4 revenue and gross margin "handily" topped estimates and that its FY19 reported revenue growth guidance also beat expectations, which he calls early evidence of its business model innovation and execution. While he expects Nike's transition to a higher margin, higher return model will take time, he is encouraged by the early signs of progress and thinks the shift will support a premium multiple compared to historical levels, Duffy tells investors. He maintains a Buy rating on Nike and raised his price target on the shares to $90 from $87.
JWN Nordstrom
$51.11

-2.43 (-4.54%)

07/05/18
DBAB
07/05/18
NO CHANGE
DBAB
Buy
Nordstrom to detail EBIT expansion at investor day, says Deutsche Bank
Deutsche Bank analyst Paul Trussell believes Nordstrom at the company's first investor day on July 10 will lay out the path back to EBIT expansion with a further moderation in spending growth, and set longer-term comp and profitability targets. The analyst says he's heading into the event with optimism despite "much investor skepticism" that persists. He also expects Nordstrom's capital return story to accelerate as spending is projected to decelerate through fiscal 2022, combined with a likely new share buyback program. Trussell keeps a Buy rating on Nordstrom shares.
07/09/18
KEYB
07/09/18
DOWNGRADE
KEYB
Sector Weight
Urban Outfitters downgraded to Sector Weight from Overweight at KeyBanc
KeyBanc analyst Edward Yruma downgraded Urban Outfitters to Sector Weight. The analyst downgraded shares of Nordstrom (JWN).
07/10/18
07/10/18
DOWNGRADE

Sector Weight
Nordstrom downgraded to Sector Weight on risk/reward prospects at KeyBanc
As previously reported, KeyBanc analyst Edward Yruma downgraded Nordstrom to Sector Weight from Overweight to reflect a more balanced near-term risk reward prospects. The analyst remains impressed by the company's openness to reinventing itself, but initiatives like pop-ups, product exclusives, and remodels have been unable to counter the natural traffic migration to e-commerce at the full-line stores. While capex may fall as previously indicated, more dramatic changes may be required to improve performance, he adds.
07/09/18
KEYB
07/09/18
DOWNGRADE
KEYB
Sector Weight
Nordstrom downgraded to Sector Weight from Overweight at KeyBanc
KeyBanc analyst Edward Yruma downgraded Nordstrom to Sector Weight.
URBN Urban Outfitters
$45.60

-0.2 (-0.44%)

07/10/18
07/10/18
DOWNGRADE

Sector Weight
Urban Outfitters downgraded to Sector Weight on risk/reward prospects at KeyBanc
As previously reported, KeyBanc analyst Edward Yruma downgraded Urban Outfitters to Sector Weight from Overweight to reflect more balanced near-term risk reward prospects. The analyst believes comp comparisons will get increasingly difficult in the 2H and earnings growth will need to be driven by gross margin expansion.
06/12/18
BARD
06/12/18
NO CHANGE
Target $53
BARD
Outperform
Urban Outfitters price target raised to $53 from $45 at Baird
Baird analyst Mark Altschwager raised his price target on Urban Outfitters to $53 from $45 following the company's filing that indicated its quarter-to-date comps are tracking up mid-teens and ahead of expectations. The analyst raised his estimates while incorporating stronger sales and margin leverage. Altschwager reiterated his Outperform rating on Urban Outfitters shares.
07/03/18
LOOP
07/03/18
NO CHANGE
Target $50
LOOP
Buy
Urban Outfitters price target raised to $50 from $47 at Loop Capital
Loop Capital analyst Laura Champine raised her price target on Urban Outfitters to $50, saying she sees ongoing momentum in apparel sales and believes the company's positive fashion trends will lead to its upside growth. The analyst anticipates comps in every segment to accelerate throughout 2018, with further potential for margin expansion because of reduced promotional activity. Champine keeps her Buy rating on Urban Outfitters and also raises her FY18 EPS forecast to $2.60 from $2.48, saying investors should buy the stock ahead of sales and earnings catalysts.

TODAY'S FREE FLY STORIES

NTGN

Neon Therapeutics

$8.88

0.56 (6.73%)

14:30
10/21/18
10/21
14:30
10/21/18
14:30
Conference/Events
Neon Therapeutics management to meet with Morgan Stanley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 26

    Oct

  • 07

    Nov

GTHX

G1 Therapeutics

$46.88

-0.07 (-0.15%)

14:13
10/21/18
10/21
14:13
10/21/18
14:13
Hot Stocks
G1 presents additional data from randomized Phase 2 trial in first-line SCLC »

G1 Therapeutics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

NCNA

NuCana

$18.90

1.9 (11.18%)

14:09
10/21/18
10/21
14:09
10/21/18
14:09
Hot Stocks
NuCana reports additional data on NUC-1031 in advanced biliary tract cancer »

NuCana announced combined…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

LPTX

Leap Therapeutics

$6.44

-0.17 (-2.57%)

, MRK

Merck

$72.34

0.12 (0.17%)

14:05
10/21/18
10/21
14:05
10/21/18
14:05
Hot Stocks
Leap Therapeutics presents esophagogastric cancer data »

Leap Therapeutics (LPTX)…

LPTX

Leap Therapeutics

$6.44

-0.17 (-2.57%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

INCY

Incyte

$66.09

1.66 (2.58%)

14:02
10/21/18
10/21
14:02
10/21/18
14:02
Hot Stocks
Incyte announces positive interim data from Phase 2 trial of Pemigatinib »

Incyte announced updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

, BAYRY

Bayer

$0.00

(0.00%)

13:58
10/21/18
10/21
13:58
10/21/18
13:58
Hot Stocks
Loxo's larotrectinib delivers 81% ORR in expanded dataset of 109 TRK fusion cancer »

Bayer (BAYRY) and Loxo…

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

BAYRY

Bayer

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 23

    Oct

  • 29

    Oct

  • 26

    Nov

  • 27

    Nov

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

, BAYRY

Bayer

$0.00

(0.00%)

13:53
10/21/18
10/21
13:53
10/21/18
13:53
Hot Stocks
Loxo announces larotrectinib clinical update in patients with TRK fusion cancers »

Loxo Oncology (LOXO)…

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

BAYRY

Bayer

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 23

    Oct

  • 29

    Oct

  • 26

    Nov

  • 27

    Nov

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

13:45
10/21/18
10/21
13:45
10/21/18
13:45
Hot Stocks
Mirati announces updated data from ongoing trial of single agent sitravatinib »

Mirati Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

RHHBY

Roche

$0.00

(0.00%)

13:39
10/21/18
10/21
13:39
10/21/18
13:39
Hot Stocks
Entrectinib shrank tumors in people with NTRK fusion-positive solid tumors »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Nov

  • 24

    Dec

GILD

Gilead

$73.27

-0.9 (-1.21%)

, GLPG

Galapagos NV

$107.66

2.29 (2.17%)

13:34
10/21/18
10/21
13:34
10/21/18
13:34
Hot Stocks
Gilead, Galapagos NV announced data from Phase 3 FINCH2 trial of filgotinib »

Gilead Sciences (GILD)…

GILD

Gilead

$73.27

-0.9 (-1.21%)

GLPG

Galapagos NV

$107.66

2.29 (2.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 07

    Nov

BLRX

BioLineRx

$0.98

-0.22 (-18.33%)

, MRK

Merck

$72.34

0.12 (0.17%)

13:27
10/21/18
10/21
13:27
10/21/18
13:27
Hot Stocks
BioLineRx discloses additional data from Phase 2a COMBAT/KEYNOTE-202 study »

BioLineRx (BLRX)…

BLRX

BioLineRx

$0.98

-0.22 (-18.33%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

ADAP

Adaptimmune

$10.79

-0.09 (-0.83%)

13:22
10/21/18
10/21
13:22
10/21/18
13:22
Hot Stocks
Adaptimmune presents updated data from ongoing MAGE-A10, MAGE-A4 studies »

Adaptimmune Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

13:02
10/21/18
10/21
13:02
10/21/18
13:02
Hot Stocks
Genentech's Tecentriq, Abraxane combo demonstrates positive Phase III results »

Genentech, a member of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 07

    Nov

  • 24

    Dec

PFE

Pfizer

$44.50

0.48 (1.09%)

12:56
10/21/18
10/21
12:56
10/21/18
12:56
Hot Stocks
Pfizer presents overall survival data from PALOMA-3 trial of Ibrance »

Pfizer announced detailed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

  • 07

    Nov

MRK

Merck

$72.34

0.12 (0.17%)

12:52
10/21/18
10/21
12:52
10/21/18
12:52
Hot Stocks
Merck presents early data for STING agonist in advanced solid tumors/lymphomas »

Merck announced the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

DVAX

Dynavax

$10.90

-0.47 (-4.13%)

, MRK

Merck

$72.34

0.12 (0.17%)

12:47
10/21/18
10/21
12:47
10/21/18
12:47
Hot Stocks
Dynavax's SD-101, Keytruda combo still shows 70% ORR in Advanced Melanoma »

Dynavax (DVAX) presented…

DVAX

Dynavax

$10.90

-0.47 (-4.13%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

EXEL

Exelixis

$16.27

-0.25 (-1.51%)

12:44
10/21/18
10/21
12:44
10/21/18
12:44
Hot Stocks
Exelixis announces results from data analysis of CABOSUN, METEOR trials »

Exelixis announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 01

    Nov

  • 07

    Nov

  • 27

    Nov

  • 14

    Jan

AGEN

Agenus

$1.97

-0.025 (-1.26%)

12:39
10/21/18
10/21
12:39
10/21/18
12:39
Hot Stocks
Agenus presents clinical data on PD-1, CTLA-4 at ESMO 2018 »

Agenus presented updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

OMED

OncoMed

$2.47

-0.17 (-6.44%)

12:37
10/21/18
10/21
12:37
10/21/18
12:37
Hot Stocks
OncoMed announces interim phase 1b results for Navicixizumab, Paclitaxel combo »

OncoMed Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

, MRK

Merck

$72.34

0.12 (0.17%)

12:34
10/21/18
10/21
12:34
10/21/18
12:34
Hot Stocks
ImmunoGen presents initial data from FORWARD II expansion cohort »

ImmunoGen (IMGN)…

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

MRK

Merck

$72.34

0.12 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 02

    Nov

  • 11

    Jan

  • 16

    Feb

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

12:30
10/21/18
10/21
12:30
10/21/18
12:30
Hot Stocks
Opdivo, Yervoy combo shows promising results in advanced form of bladder cancer »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 29

    Oct

  • 07

    Nov

MRK

Merck

$72.34

0.12 (0.17%)

12:26
10/21/18
10/21
12:26
10/21/18
12:26
Hot Stocks
Merck's Keytruda shows complete response rate of nearly 40% in high-risk NMIBC »

Merck announced the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 25

    Oct

  • 29

    Oct

  • 11

    Jan

  • 16

    Feb

TSRO

Tesaro

$41.81

-1.19 (-2.77%)

12:18
10/21/18
10/21
12:18
10/21/18
12:18
Hot Stocks
Tesaro presents Phase 1 GARNET data of TSR-042 in MSI-H endometrial cancer »

Tesaro summarized updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 07

    Nov

UDR

UDR, Inc.

09:37
10/21/18
10/21
09:37
10/21/18
09:37
Downgrade
UDR, Inc. rating change at Evercore ISI »

UDR, Inc. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 07

    Nov

AVB

AvalonBay

$178.01

1.725 (0.98%)

09:37
10/21/18
10/21
09:37
10/21/18
09:37
Downgrade
AvalonBay rating change  »

AvalonBay downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.